1. Pink Sheet

EU’s AMR Transferable Exclusivity Voucher Plan 'Not Fit For Purpose'

 
• By Ian Schofield

A European public health NGO has disputed the suggestion that a transferable exclusivity extension is the answer to the lack of innovative antimicrobial drugs in company pipelines.

Bacteria
Antimicrobial resistance is an ongoing challenge for the pharma sector • Source: Shutterstock

The transferable exclusivity voucher idea being proposed by the European Commission as a way of stimulating the development of new antibiotics in the EU is a “narrow and inefficient” mechanism that could actually exacerbate the problems related to antimicrobial resistance (AMR), says the European Public Health Alliance.

Under the scheme, a company that brought a new antimicrobial to the market would receive a “transferable exclusivity extension” (TEE)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.